What 13 Analyst Ratings Have To Say About Incyte
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
What 13 Analyst Ratings Have To Say About Incyte
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Second Setback For Incyte’s LIMBER Program – Analyst Says ‘Resolution Timelines Unclear To Assess Impact’
The FDA issued a complete response letter (CRL) to Incyte Corporation (NASDAQ:INCY) ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD)…
Second Setback For Incyte’s LIMBER Program – Analyst Says ‘Resolution Timelines Unclear To Assess Impact’
The FDA issued a complete response letter (CRL) to Incyte Corporation (NASDAQ:INCY) ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD)…
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
The FDA granted accelerated approval to Incyte Corporation’s (NASDAQ:INCY) Zynyz (retifanlimab-dlwr) for adult patients with metastatic or recurrent locally advanced Merkel cell…
Analyst Writes Incyte’s Opzelura Provides Deepening, Relapse Prevention; Povo Data Intriguing In Depigmented Skin Disorder
Incyte Corporation (NASDAQ:INCY) announced new data from a Phase 2b trial of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult…
Incyte Announced Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo; Said Patients Treated With Povorcitinib Experienced Improvements In Total Body And Facial Repigmentation
Incyte (Nasdaq: INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.
Caris Life Sciences Announced A Strategic Research Partnership With Incyte To Augment Precision Medicine Approaches For Incyte’s Oncology Pipeline; Deal Terms Not Disclosed
Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs.
For drug candidates developed under the
Cowen & Co. Maintains Outperform on Incyte, Raises Price Target to $100
Cowen & Co. analyst Marc Frahm maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $95 to $100.
Piper Sandler Maintains Overweight on Incyte, Maintains $100 Price Target
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and maintains $100 price target.